Qiagen (NYSE:QGEN) Shares Bought by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank increased its position in Qiagen (NYSE:QGEN) by 44.5% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 218,127 shares of the company’s stock after acquiring an additional 67,143 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Qiagen were worth $9,852,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of QGEN. GAMMA Investing LLC raised its position in Qiagen by 806.5% during the third quarter. GAMMA Investing LLC now owns 562 shares of the company’s stock worth $26,000 after acquiring an additional 500 shares during the last quarter. Toronto Dominion Bank purchased a new position in shares of Qiagen during the 2nd quarter worth approximately $27,000. Massmutual Trust Co. FSB ADV raised its position in shares of Qiagen by 39.8% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock worth $39,000 after purchasing an additional 243 shares during the last quarter. CWM LLC lifted its stake in Qiagen by 12.0% in the 2nd quarter. CWM LLC now owns 2,505 shares of the company’s stock valued at $103,000 after buying an additional 269 shares in the last quarter. Finally, Headlands Technologies LLC grew its holdings in Qiagen by 396.6% during the 2nd quarter. Headlands Technologies LLC now owns 2,741 shares of the company’s stock valued at $113,000 after buying an additional 2,189 shares during the last quarter. 70.00% of the stock is owned by hedge funds and other institutional investors.

Qiagen Stock Down 0.7 %

Shares of NYSE:QGEN opened at $43.43 on Monday. Qiagen has a 12-month low of $39.03 and a 12-month high of $47.44. The stock’s 50-day moving average price is $43.22 and its two-hundred day moving average price is $43.70. The company has a current ratio of 2.17, a quick ratio of 1.89 and a debt-to-equity ratio of 0.39. The firm has a market cap of $9.91 billion, a price-to-earnings ratio of 111.36, a PEG ratio of 3.37 and a beta of 0.41.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on QGEN shares. HSBC cut Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price target for the company. in a report on Thursday, October 17th. Hsbc Global Res raised shares of Qiagen to a “hold” rating in a research note on Thursday, October 17th. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $50.88.

Qiagen Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.